Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)
Launched by KISSEI PHARMACEUTICAL CO., LTD. · Oct 30, 2014
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patients who experienced fewer than three SBMs per week for more than 6 months prior to the enrollment.
- • The patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation.
- Exclusion Criteria:
- • Patients who have secondary constipation caused by systemic disorder.
- • Patients who have organic constipation.
- • Patients who received intestinal resection.
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies to address unmet medical needs. With a strong focus on specialty pharmaceuticals, Kissei leverages advanced technologies and rigorous clinical research to create effective treatments in areas such as urology, nephrology, and diabetes management. Committed to enhancing patient outcomes, Kissei collaborates with healthcare professionals and research institutions worldwide, ensuring a comprehensive approach to drug development that aligns with global health standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo And Other Japanese City, , Japan
Patients applied
Trial Officials
Tatsuro Takei
Study Director
Kissei Pharmaceutical Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials